Biotech entity
All 2 tracked stories fall under one category: pharma. FulcrumSec is most often covered alongside Novo Nordisk, which appears in 2 of these 2 stories. That works out to roughly 1.2 stories per week across a 12-day span. Source depth averages 2.5 original sources per story, versus 4.4 across the same-window beat baseline.
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. FulcrumSec is most often covered alongside Novo Nordisk, which appears in 2 of these 2 stories. That works out to roughly 1.2 stories per week across a 12-day span. Source depth averages 2.5 original sources per story, versus 4.4 across the same-window beat baseline. The 8.5 average consequence score is above the beat benchmark of 6.7 in the same window. This profile follows 2 Biotech stories mentioning FulcrumSec across the period from June 17, 2026 to June 28, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering FulcrumSec. Shared-story counts are live from our verified record — not editorial picks.
Biotech giant Novo Nordisk faces a catastrophic IP theft as hackers claim to have stolen over a terabyte of proprietary drug data, including formulas and trial results, and are now exploring private sales after a $25 million ransom was refused.
Source: yahoo.com · thestar.com.my
FulcrumSec's breach of Novo Nordisk could jeopardize years of R&D as stolen data includes proprietary information on released and unreleased drugs, trial data, and manufacturing processes. With the extortion failure and potential data sale, rival pharma firms may gain competitive intelligence, threatening Novo's market position.
FulcrumSec is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
